Κλαύδιος Γαληνός
Δωρεάν εγγραφή Αποκτήσετε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr για έναν μήνα
Έλεγχος συγχορήγησης Ελέγξτε την αγωγή σας για αντενδείξεις και αλληλεπιδράσεις μεταξύ των φαρμάκων
Μητρότητα και φάρμακα Ενημερωθείτε για την ασφάλεια χορήγησης ενός φαρμάκου κατά τη διάρκεια της εγκυμοσύνης ή του θηλασμού
Συνδρομές Μάθετε περισσότερα για τα οφέλη και τις επιπλέον παροχές των συνδρομητικών προγραμμάτων
Ενδείξεις και αγωγές Βρείτε θεραπευτικές ενδείξεις και αγωγές για νόσους, συμπτώματα και ιατρικές πράξεις
Γνωρίζατε ότι... Μοιραζόμαστε μαζί σας γεγονότα της πορείας του Galinos.gr από το 2011 μέχρι σήμερα

FLIXOTIDE EVOHALER Pressurised inhalation, suspension (2018)

Αναφορές

Βιβλιογραφική αναφορά

Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή

Περιεχόμενα

Name of the medicinal product

Flixotide 50 micrograms Evohaler. Flixotide 125 micrograms Evohaler. Flixotide 250 micrograms Evohaler.

Qualitative and quantitative composition

Flixotide 50 micrograms Evohaler, Flixotide 125 micrograms Evohaler and Flixotide 250 micrograms Evohaler are pressurised inhalation, suspensions, delivering either 50, 125 or 250 micrograms of fluticasone ...

Pharmaceutical form

Pressurised inhalation, suspension. Flixotide Evohaler does not contain any chlorofluorocarbons (CFCs).

Therapeutic indications

Fluticasone propionate given by inhalation offers prophylactic treatment for asthma. Adults Mild asthma Patients requiring intermittent symptomatic bronchodilator asthma medication on a regular daily basis. ...

Posology and method of administration

Patients should be made aware of the prophylactic nature of therapy with inhaled fluticasone propionate and that it should be taken regularly even when they are asymptomatic. If patients find that relief ...

Contraindications

Hypersensitivity to the active substance or any of the excipients listed in section 6.1.

Special warnings and precautions for use

The management of asthma should follow a stepwise programme, and patient response should be monitored clinically and by lung function tests. Patients' inhaler technique should be checked regularly to make ...

Interaction with other medicinal products and other forms of interaction

Under normal circumstances, low plasma concentrations of fluticasone propionate are achieved after inhaled dosing, due to extensive first pass metabolism and high systemic clearance mediated by cytochrome ...

Fertility, pregnancy and lactation

Fertility There are no data on human fertility. Animal studies indicate no effects of fluticasone propionate on male or female fertility. Pregnancy There are limited data in pregnant women. Administration ...

Effects on ability to drive and use machines

Fluticasone propionate is unlikely to produce an effect.

Undesirable effects

Adverse events are listed below by system organ class and frequency. Frequencies are defined as: very common (≥1/10), common (≥1/100 and <1/10), uncommon (≥1/1000 and <1/100), rare (≥1/10,000 and <1/1000), ...

Overdose

Acute Inhalation of the drug in doses in excess of those recommended may lead to temporary suppression of adrenal function. This does not necessitate emergency action being taken. In these patients treatment ...

Pharmacodynamic properties

Fluticasone propionate given by inhalation at recommended doses has a potent glucocorticoid anti-inflammatory action within the lungs, resulting in a reduction of both symptoms and exacerbations of asthma, ...

Pharmacokinetic properties

In healthy subjects the mean systemic bioavailability of Flixotide Evohaler is 28.6%. In patients with asthma (FEV<sub>1</sub> <75% predicted) the mean systemic absolute bioavailability was reduced by ...

Preclinical safety data

Toxicology has shown only those class effects typical of potent corticosteroids, and these only at doses greatly in excess of that proposed for therapeutic use. No novel effects were identified in repeat ...

List of excipients

HFA 134a

Incompatibilities

None reported.

Shelf life

24 months.

Special precautions for storage

Do not store above 30°C (86°F). Do not refrigerate or freeze. Protect from frost and direct sunlight. As with most medicines in pressurised canisters, the therapeutic effect of this medication may decrease ...

Nature and contents of container

An inhaler comprising an aluminium alloy can sealed with a metering valve, actuator and dust cap. Each canister contains 120 metered actuations of either 50, 125 or 250 micrograms of fluticasone propionate. ...

Special precautions for disposal and other handling

The aerosol spray is inhaled through the mouth into the lungs. After shaking the inhaler the patient should exhale, the mouthpiece should be placed in the mouth and the lips closed around it. The actuator ...

Marketing authorization holder

Glaxo Wellcome UK Ltd, trading as GlaxoSmithKline UK, Stockley Park West, Uxbridge, Middlesex, UB11 1BT

Marketing authorization number(s)

Flixotide 50 micrograms Evohaler: PL 10949/0324 Flixotide 125 micrograms Evohaler: PL 10949/0265 Flixotide 250 micrograms Evohaler: PL 10949/0266

Date of first authorization / renewal of the authorization

Flixotide Evohaler 50 micrograms: 27 June 2000 Flixotide Evohaler 125/250 micrograms: 14 March 2000

Date of revision of the text

12 December 2018

Πηγαίο έγγραφο

Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση:

Μπορείτε να υποστηρίξετε τον Γαληνό στην αποστολή του να παρέχει δωρεάν έγκυρη πληροφόρηση για κάθε φάρμακο απενεργοποιώντας το Ad Blocker για αυτόν τον ιστότοπο.